Document Detail


Morphological variants of leukemic cells in B chronic lymphocytic leukemia are associated with different T cell and NK cell abnormalities.
MedLine Citation:
PMID:  9257876     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
B chronic lymphocytic leukemia (B-CLL) is a heterogeneous disease. The different morphological variants of leukemic B cells appear to define different clinical groups of patients. Several abnormalities have been found in T lymphocytes and natural killer (NK) cells from B-CLL patients. We have investigated the phenotypic and functional characteristics of purified CD2+ cells from B-CLL patients at Binet's stage A and classified according to the neoplastic B lymphocyte morphology criteria: 32 patients with typical B-CLL and 12 patients with atypical B-CLL. Forty-three age and sex matched healthy controls were also studied. In fresh purified CD2+ cells from typical B-CLL patients, percentages of CD4+, CD4+CD45RA+, CD8+CD45RA+ T lymphocytes and CD3-CD56+ (NK) cells were significantly higher than those found in atypical B-CLL patients. However, in DC2+ cells from typical B-CLL patients, percentages of CD3+, CD3+DR+, CD8+, CD4+CD45RO+, and CD3+CD56+ cells were significantly lower than those found in atypical B-CLL patients. Increased percentage of NK cells was only found in typical B-CLL patients. The proliferative response and the production of interleukin (IL)-2 and IL-4 by phytohemagglutinin (PHA) stimulated CD2+ cells were significantly higher in typical B-CLL patients than in atypical B-CLL patients. We concluded that different patterns of phenotypic and functional alterations in the T lymphocytes and NK cells of B-CLL patients are found in patients with typical or atypical B-CLL defined according to the morphology of the leukemic cells.
Authors:
E Reyes; A Prieto; F Carrion; J Garcia-Suarez; F Esquivel; M Alvarez-Mon
Related Documents :
7540066 - Expression of cd27 and its ligand, cd70, on chronic lymphocytic leukemia b cells.
8332446 - Interleukin-4 and the two isoforms of cd23 antigen: their possible contribution to the ...
12828856 - Selection of oligonucleotide aptamers with enhanced uptake and activation of human leuk...
1714406 - Distinct morphophenotypic features of chronic b-cell leukaemias identified with cd1c an...
8095306 - Increased viral burden and cytopathicity correlate temporally with cd4+ t-lymphocyte de...
22938486 - Biological response modifiers influence structure function relationship of hematopoieti...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American journal of hematology     Volume:  55     ISSN:  0361-8609     ISO Abbreviation:  Am. J. Hematol.     Publication Date:  1997 Aug 
Date Detail:
Created Date:  1997-09-03     Completed Date:  1997-09-03     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  7610369     Medline TA:  Am J Hematol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  175-82     Citation Subset:  IM    
Affiliation:
Principe de Asturias University Hospital, Department of Medicine, University of Alcala de Henares, Madrid, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Aged, 80 and over
Antigens, CD2 / analysis
Antigens, CD3 / analysis
Antigens, CD4 / analysis
Antigens, CD45 / analysis
Antigens, CD56 / analysis
Antigens, CD8 / analysis
B-Lymphocytes / pathology*
Female
Humans
Interleukin-2 / biosynthesis
Interleukin-4 / biosynthesis
Killer Cells, Natural / immunology*
Leukemia, Lymphocytic, Chronic, B-Cell / immunology*,  pathology*
Lymphocyte Count
Male
Middle Aged
T-Lymphocytes / immunology*
Chemical
Reg. No./Substance:
0/Antigens, CD2; 0/Antigens, CD3; 0/Antigens, CD4; 0/Antigens, CD56; 0/Antigens, CD8; 0/Interleukin-2; 207137-56-2/Interleukin-4; EC 3.1.3.48/Antigens, CD45

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Intercellular adhesion molecule-1 deficiency protects MRL/MpJ-Fas(lpr) mice from early lethality.
Next Document:  Increased tissue factor pathway inhibitor in patients with acute myocardial infarction.